Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of ASP1585 Granules vs Capsules
NCT02531204Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bixalomer in hyperphosphatemia (2 arms), sponsored by Astellas Pharma. Primary endpoint: Average daily amount of urine phosphorus change from baseline. Started Aug 2014; status: completed.
02
Drugs
bixalomer
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02531204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531204.